Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer - PubMed (original) (raw)
Clinical Trial
. 2018 Sep;24(9):1449-1458.
doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.
Razvan Cristescu 2, Adam J Bass 3, Kyoung-Mee Kim 4, Justin I Odegaard 5, Kyung Kim 1, Xiao Qiao Liu 2, Xinwei Sher 2, Hun Jung 2, Mijin Lee 1, Sujin Lee 1, Se Hoon Park 1, Joon Oh Park 1, Young Suk Park 1, Ho Yeong Lim 1, Hyuk Lee 6, Mingew Choi 7, AmirAli Talasaz 5, Peter Soonmo Kang 2, Jonathan Cheng 2, Andrey Loboda 2, Jeeyun Lee 8, Won Ki Kang 1
Affiliations
- PMID: 30013197
- DOI: 10.1038/s41591-018-0101-z
Clinical Trial
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al. Nat Med. 2018 Sep.
Abstract
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial. In patients with microsatellite instability-high and Epstein-Barr virus-positive tumors, which are mutually exclusive, dramatic responses to pembrolizumab were observed (overall response rate (ORR) 85.7% in microsatellite instability-high mGC and ORR 100% in Epstein-Barr virus-positive mGC). For the 55 patients for whom programmed death-ligand 1 (PD-L1) combined positive score positivity was available (combined positive score cut-off value ≥1%), ORR was significantly higher in PD-L1(+) gastric cancer when compared to PD-L1(-) tumors (50.0% versus 0.0%, P value <0.001). Changes in ctDNA levels at six weeks post-treatment predicted response and progression-free survival, and decreased ctDNA was associated with improved outcomes. Our findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.
Comment in
- Immunotherapy-responsive gastric cancers identified.
Sidaway P. Sidaway P. Nat Rev Clin Oncol. 2018 Oct;15(10):590. doi: 10.1038/s41571-018-0079-y. Nat Rev Clin Oncol. 2018. PMID: 30061740 No abstract available. - Immunotherapy-responsive gastric cancers identified.
Sidaway P. Sidaway P. Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):582. doi: 10.1038/s41575-018-0063-0. Nat Rev Gastroenterol Hepatol. 2018. PMID: 30127489 No abstract available. - Predictive markers in gastric cancer immunotherapy treatment-are we there yet?
Mehta R, Almhanna K. Mehta R, et al. Transl Gastroenterol Hepatol. 2019 Jan 24;4:4. doi: 10.21037/tgh.2019.01.01. eCollection 2019. Transl Gastroenterol Hepatol. 2019. PMID: 30854491 Free PMC article. No abstract available. - How to better select patients with advanced gastric cancer for immunotherapy.
Zaanan A, Taieb J. Zaanan A, et al. Transl Gastroenterol Hepatol. 2019 Jan 31;4:6. doi: 10.21037/tgh.2019.01.06. eCollection 2019. Transl Gastroenterol Hepatol. 2019. PMID: 30854493 Free PMC article. No abstract available.
Similar articles
- Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer.
Kwon M, Hong JY, Kim ST, Kim KM, Lee J. Kwon M, et al. Pathol Res Pract. 2020 Jun;216(6):152947. doi: 10.1016/j.prp.2020.152947. Epub 2020 Apr 11. Pathol Res Pract. 2020. PMID: 32284250 - Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T. Kawazoe A, et al. Gastric Cancer. 2019 Jan;22(1):69-76. doi: 10.1007/s10120-018-0843-9. Epub 2018 Jun 1. Gastric Cancer. 2019. PMID: 29859006 - Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA, Ramos MFKP, Faraj SF, Dias AR, Yagi OK, Zilberstein B, Cecconello I, Alves VAF, de Mello ES, Ribeiro U Jr. Pereira MA, et al. J Surg Oncol. 2018 Apr;117(5):829-839. doi: 10.1002/jso.25022. Epub 2018 Mar 13. J Surg Oncol. 2018. PMID: 29534305 - The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT, de Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ. Toh JWT, et al. Clin Colorectal Cancer. 2016 Dec;15(4):285-291. doi: 10.1016/j.clcc.2016.07.007. Epub 2016 Jul 22. Clin Colorectal Cancer. 2016. PMID: 27553906 Review.
Cited by
- SUMOylation-induced membrane localization of TRPV1 suppresses proliferation and migration in gastric cancer cells.
Yang Y, Gu X, Weng W, Cheng J, Huang O, Pan SJ, Li Y. Yang Y, et al. Cell Commun Signal. 2024 Sep 30;22(1):465. doi: 10.1186/s12964-024-01850-0. Cell Commun Signal. 2024. PMID: 39350261 Free PMC article. - Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review.
Corallo S, Lasagna A, Filippi B, Alaimo D, Tortorella A, Serra F, Vanoli A, Pedrazzoli P. Corallo S, et al. Pathogens. 2024 Aug 28;13(9):728. doi: 10.3390/pathogens13090728. Pathogens. 2024. PMID: 39338919 Free PMC article. Review. - Dihydrotestosterone Enhances MICA-Mediated Immune Responses to Epstein-Barr Virus-Associated Gastric Carcinoma.
Seo D, Byun H, Cho M, Lee SH, Youn S, Lee J, Jung I, Cho H, Kang H. Seo D, et al. Cancers (Basel). 2024 Sep 21;16(18):3219. doi: 10.3390/cancers16183219. Cancers (Basel). 2024. PMID: 39335190 Free PMC article. - Comprehensive analysis of the potential biological significance of CCL5 in pan-cancer prognosis and immunotherapy.
Shan J, Xu Y, Lun Y. Shan J, et al. Sci Rep. 2024 Sep 27;14(1):22138. doi: 10.1038/s41598-024-73251-9. Sci Rep. 2024. PMID: 39333254 Free PMC article. - Integrative analysis of the immunological significances of guanylate binding protein family genes in microsatellite stability colorectal cancer.
Wang X, Han T, Wang Y, Yang R, Yang Q, Li J. Wang X, et al. Heliyon. 2024 Sep 10;10(18):e37741. doi: 10.1016/j.heliyon.2024.e37741. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39315131 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials